Recombinant CHO cell strain capable of stably expressing GPC3 and application thereof

Abstract

The invention discloses a recombinant CHO cell strain capable of stably expressing GPC3 and an application thereof. The preservation number of the CHO cell strain is CGMCC No.18881, the GPC3 is encoded by a cDNA sequence shown in the formula of SEQ ID No. 1, an antigen produced by the recombinant CHO cell strain is used for preparing a GPC3 monoclonal antibody, and the recombinant CHO cell strainis used for preparing a GPC3 antibody. The folate reductase defect type CHO cells are lack of endogenous dihydrofolate reductase, when an expression vector containing a dihydrofolate reductase gene and a target gene is co-transfected, the dihydrofolate reductase gene and the target gene are generally integrated at the same site of a host chromosome, and then in the presence of a competitive inhibitor-methotrexate of dihydrofolate reductase, the increasing of the copy number of the dhfr gene is driven to achieve the purpose of increasing the expression quantity of the target gene, so that a stable cell line for stably and efficiently expressing GPC3 is constructed, and the technical blank is filled.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a recombinant CHO cell strain stably expressing GPC3 and an application thereof. Background technique [0002] Hepatocellular carcinoma (HCC) is the fifth most common cancer with a high incidence in the world. About 110,000 people die from liver cancer every year in my country, accounting for 45% of the world's liver cancer deaths. At present, surgical resection of the tumor is still the best and fastest method for the treatment of HCC. However, most patients have lost the best opportunity for treatment when they go to the doctor, and only 10-20% of them can be surgically resected early. Even if they are surgically resected, the recurrence rate is still high. Therefore, early detection, early diagnosis, and early treatment of HCC are the key to improving the survival rate of patients, as well as the key to prognosis and treatment. [0003] Glypican 3 (glypican-3, GPC3), its gene is...

AI Technical Summary

Problems solved by technology

However, most patients have lost the best opportunity for treatment when they see a doctor, and only 10-20% of them can be surgically resected early. Even with surgical resection, the recurrence rate is still high

Images